Clinical Study
Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension
Table 1
Baseline characteristics.
| | T80/H25 | V160/H25 | Placebo |
| | N | 328 | 317 | 80 | | Age, years (SD) | 57.0 (10.7) | 56.0 (9.7) | 56.4 (10.6) | | Age group, N (%) | | | | | <65 years | 255 (77.7) | 261 (82.3) | 63 (78.8) | | ≥65 years | 73 (22.3) | 56 (17.7) | 17 (21.3) | | Gender, N (%) | | | | | Male | 181 (55.2) | 176 (55.5) | 43 (53.8) | | Female | 147 (44.8) | 141 (44.5) | 37 (46.3) | | Race, N (%) | | | | | Non-Black | 241 (73.5) | 230 (72.6) | 57 (71.3) | | Black | 87 (26.5) | 87 (27.4) | 23 (28.8) | | BMI, kg/m2 (SD) | 31.4 (6.1) | 31.8 (6.8) | 31.5 (6.2) | | SBP, mm Hg (SD) | 167.6 (5.4) | 168.3 (5.9) | 167.1 (5.8) | | DBP, mm Hg (SD) | 103.2 (4.4) | 103.4 (4.8) | 103.3 (4.0) | | Pulse rate, beats/min (SD) | 75.7 (9.9) | 75.0 (9.4) | 74.5 (8.8) |
|
|
BMI: body mass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; SD: standard deviation; T80/H25: telmisartan 80 mg/hydrochlorothiazide 25 mg; V160/H25: valsartan 160 mg/hydrochlorothiazide 25 mg.
|
